This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Mar;38(3):429-30.

doi: 10.2337/dc14-1596.

Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

Colleen Majewski¹, George L Bakris²

Affiliations

Affiliations

¹ American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL.
² American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL gbakris@gmail.com.

PMID: 25715414
PMCID: PMC4876696
DOI: 10.2337/dc14-1596

Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

Colleen Majewski et al. Diabetes Care. 2015 Mar.

. 2015 Mar;38(3):429-30.

doi: 10.2337/dc14-1596.

Authors

Colleen Majewski¹, George L Bakris²

Affiliations

¹ American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL.
² American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL gbakris@gmail.com.

PMID: 25715414
PMCID: PMC4876696
DOI: 10.2337/dc14-1596

No abstract available

PubMed Disclaimer

Similar articles

Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ. Bloch MJ. J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001. J Am Soc Hypertens. 2016. PMID: 27408945 No abstract available.
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M, Rezaie P, Gao HK, Kengne AP. Mazidi M, et al. J Am Heart Assoc. 2017 May 25;6(6):e004007. doi: 10.1161/JAHA.116.004007. J Am Heart Assoc. 2017. PMID: 28546454 Free PMC article. Review.
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Powell J, Miller SA, Taylor JR. Powell J, et al. South Med J. 2015 Feb;108(2):82-90. doi: 10.14423/SMJ.0000000000000233. South Med J. 2015. PMID: 25688892 Review.
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
Diamant M, Morsink LM. Diamant M, et al. Lancet. 2013 Sep 14;382(9896):917-8. doi: 10.1016/S0140-6736(13)60902-2. Epub 2013 Jul 12. Lancet. 2013. PMID: 23850056 No abstract available.
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. Yale JF, et al. Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22. Diabetes Obes Metab. 2014. PMID: 24965700 Clinical Trial.

See all similar articles

Cited by

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC. Singh JS, et al. Cardiovasc Diabetol. 2016 Jul 15;15:97. doi: 10.1186/s12933-016-0419-0. Cardiovasc Diabetol. 2016. PMID: 27422625 Free PMC article. Clinical Trial.
Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.
El Hage L, Kashyap SR, Rao P. El Hage L, et al. J Prim Care Community Health. 2019 Jan-Dec;10:2150132719895188. doi: 10.1177/2150132719895188. J Prim Care Community Health. 2019. PMID: 31894715 Free PMC article.
Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.
Penna C, Andreadou I, Aragno M, Beauloye C, Bertrand L, Lazou A, Falcão-Pires I, Bell R, Zuurbier CJ, Pagliaro P, Hausenloy DJ. Penna C, et al. Br J Pharmacol. 2020 Dec;177(23):5312-5335. doi: 10.1111/bph.14993. Epub 2020 Mar 9. Br J Pharmacol. 2020. PMID: 31985828 Free PMC article. Review.
SGLT2 inhibitors: the latest "new kids on the block"!
Cefalu WT, Riddle MC. Cefalu WT, et al. Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048. Diabetes Care. 2015. PMID: 25715412 Free PMC article. No abstract available.
Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
Kuriyama S. Kuriyama S. Clin Exp Nephrol. 2019 Mar;23(3):304-312. doi: 10.1007/s10157-018-1673-0. Epub 2018 Nov 26. Clin Exp Nephrol. 2019. PMID: 30478731 Review.

See all "Cited by" articles

References

1. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807–824 - PubMed
1. Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 2014;74:2191–2209 - PubMed
1. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330–339 - PubMed
1. Tikkanen I, Narko K, Zeller C, et al.; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38:420–428 - PubMed
1. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence . NICE hypertension guideline 2011: evidence based evolution. BMJ 2012;344:e181. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

UL1 TR000430/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

NODES